A biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases.


Updates from The Motley Fool

Latest updates on Progenics Pharmaceuticals from Fool.com.
3 Top Stocks in Healthcare

Find out why Align Technology, Mazor Robotics, and Progenics Pharmaceuticals are three of the bes...



Stock Performance

View Interactive PGNX Charts
Sponsored by

Key Data Points

Primary metrics and data points about Progenics Pharmaceuticals.
Current Price: $8.49
Prev Close: $8.47
Open: $8.46
Bid: $8.50
Ask: $8.68
Day's Range: $8.31 - $8.50
52wk Range: $4.60 - $9.12
Volume: 1,965,986
Avg Vol 1,237,696
Market Cap: $626M
P/E (ttm): -12.28
EPS (ttm): ($0.69)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Progenics Pharmaceuticals.
CAPS Rating 3 out of 5
 
196 Outperform
22 Underperform
CAPS All Stars
 
32 Outperform
4 Underperform

How do you think Progenics Pharmaceuticals will perform against the market?



You pick for Progenics Pharmaceuticals is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Mark R. Baker, CEO

0% Approve

Based on 3 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Progenics Pharmaceuticals.

A biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers